BRAFi/MEKi in patients with metastatic melanoma: predictive factors of complete response
| العنوان: | BRAFi/MEKi in patients with metastatic melanoma: predictive factors of complete response |
|---|---|
| المؤلفون: | Maria Teresa Fierro, Virginia Caliendo, Simone Ribero, Simona Osella-Abate, Martina Sanlorenzo, Ottavia Malavenda, Pietro Quaglino, Paolo Fava, Chiara Astrua, Elena Marra |
| المصدر: | Future Oncology. 15:133-139 |
| بيانات النشر: | Future Medicine Ltd, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Male, 0301 basic medicine, Oncology, Cancer Research, Skin Neoplasms, MAP Kinase Kinase 1, combination therapy, 0302 clinical medicine, Piperidines, Antineoplastic Combined Chemotherapy Protocols, Oximes, MEK inhibitors, Complete response, Aged, 80 and over, Trametinib, Melanoma, Imidazoles, BRAF inhibitors, General Medicine, Middle Aged, Treatment Outcome, 030220 oncology & carcinogenesis, Female, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Metastatic melanoma, Combination therapy, Pyridones, melanoma, Pyrimidinones, 03 medical and health sciences, Internal medicine, medicine, Humans, In patient, Protein Kinase Inhibitors, Aged, Retrospective Studies, business.industry, Dabrafenib, medicine.disease, 030104 developmental biology, Survival benefit, Vemurafenib, Mutation, Azetidines, business |
| الوصف: | Aim: A survival benefit was demonstrated by dabrafenib + trametinib for metastatic BRAF-mutated melanoma patients. Best response is a strong prognostic marker for survival. Patients & methods: The specific features associated with complete response (CR) were evaluated. Results: A total of 15/66 patients achieved CR. Median size of lesions was 3 cm (range: 0.5–10). Using that value as cut-off, the CR rate was 39.3% in patients with smaller lesions and 10.5% in patients with bigger size (p = 0.006). The clinical features associated with CR were the number of metastatic sites and the largest diameter of the biggest metastatic site. Conclusion: The number of the metastases and the diameter of the largest metastatic site are associated with a higher CR rate. |
| تدمد: | 1744-8301 1479-6694 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5fa36af49f03985cb916fae76f51f9fTest https://doi.org/10.2217/fon-2018-0386Test |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....c5fa36af49f03985cb916fae76f51f9f |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17448301 14796694 |
|---|